Jazz Pharmaceuticals' Suvecaltamide (JZP385) Did Not Achieve Statistical Significance At 30Mg Versus Placebo On Primary Endpoint Of Change From Baseline To Week 12 On Essential Tremor Rating Assessment Scale Modified Composite Outcome Score
The trial also did not meet On Key Secondary Endpoint Of Clinical Global Impression-severity Scale